Disease Areas
Guardant Health Begins SHIELD Trial for Lung Cancer Early Detection
The company will enroll 10,000 high-risk patients in the trial and evaluate the ability of its SHIELD blood test to detect lung cancer early.
FDA Clears Kinnate Biopharma's IND for FGFR Inhibitor in Bile Duct, Urothelial Cancers
The firm will begin a trial evaluating KIN-3248 as a treatment for patients with FGFR2/3-altered tumors during the first half of 2022.
Mainz Biomed Taps DCN Dx to Aid European Study of Enhanced ColoAlert Assay
The diagnostics and research services firm will help Mainz recruit research partners for a study assessing new biomarker additions to its CRC early detection test.
Takeda, Point32Health Deal Could Offer Roadmap for Risk-Sharing Reimbursement in Precision Oncology
Premium
The drugmaker and insurer's outcomes-based agreement offers rebates for ALK-positive NSCLC patients who discontinue Alunbrig after three months.
AstraZeneca, Daiichi Sankyo File for FDA Enhertu Approval in Second-Line HER2-Postive Breast Cancer
The agency has accepted the firms' supplemental biologics application for the antibody-drug conjugate and is expected to make a decision by Q2 2022.
Jan 3, 2022